Cowealth Medical China Co.Ltd. Total Liabilities
Cowealth Medical China Co.Ltd. total liabilities. Based on the latest financial reports, Cowealth Medical China Co.Ltd. (603122) has total liabilities worth CN¥384.57 Million CNY (≈ $56.27 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See 603122 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Cowealth Medical China Co.Ltd. (2019–2025)
Total liabilities of Cowealth Medical China Co.Ltd. from 2019 to 2025. This chart illustrates how Cowealth Medical China Co.Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Cowealth Medical China Co.Ltd.'s assets to evaluate the company's liquid asset resilience ratio.
Cowealth Medical China Co.Ltd. Competitors by Total Liabilities
The table below lists competitors of Cowealth Medical China Co.Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
S.J.S. Enterprises Limited
NSE:SJS
|
India | Rs-8.81 Billion |
|
Bain Capital Specialty Finance Inc
NYSE:BCSF
|
USA | $1.51 Billion |
|
Jilin University Zhengyuan Info Tech
SHE:003029
|
China | CN¥589.71 Million |
|
Volaris
NYSE:VLRS
|
USA | $5.79 Billion |
|
Arizona Sonoran Copper Company Inc
TO:ASCU
|
Canada | CA$119.50 Million |
|
Bestsun Energy Co Ltd
SHG:600681
|
China | CN¥4.03 Billion |
|
Aura Biosciences Inc
NASDAQ:AURA
|
USA | $30.43 Million |
|
Bassac
PA:BASS
|
France | €1.49 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Cowealth Medical China Co.Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Cowealth Medical China Co.Ltd. balance sheet assets.
Liquidity & Leverage Metrics
Cowealth Medical China Co.Ltd. Total Liabilities Ratios Explained
Cowealth Medical China Co.Ltd. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cowealth Medical China Co.Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cowealth Medical China Co.Ltd. (2019–2025)
The table below shows the annual total liabilities of Cowealth Medical China Co.Ltd. from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥368.90 Million ≈ $53.98 Million |
+15.48% |
| 2024-12-31 | CN¥319.44 Million ≈ $46.74 Million |
+9.21% |
| 2023-12-31 | CN¥292.49 Million ≈ $42.80 Million |
-23.13% |
| 2022-12-31 | CN¥380.49 Million ≈ $55.68 Million |
+17.15% |
| 2021-12-31 | CN¥324.78 Million ≈ $47.53 Million |
-17.76% |
| 2020-12-31 | CN¥394.94 Million ≈ $57.79 Million |
+15.93% |
| 2019-12-31 | CN¥340.68 Million ≈ $49.85 Million |
-- |
About Cowealth Medical China Co.Ltd.
Cowealth Medical China Co.,Ltd. operates as a medical company in China. It offers centralized procurement services for in-vitro diagnostic reagents and consumables; platform for decision-making and analysis, commercialization of achievements in medical science and technology; a multi-channel coaxial time audio video imaging platform; and an AI-assisted system for clinical diagnosis. The company w… Read more